1. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, et al.Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.Oncology (Williston Park). 2002;16(5 Suppl 5):16-8.
  2. Lutz MP, Kaechele V, Berger LB, Rebstock A, Koehne CH, Rudi J.Weekly epirubicin and paclitaxel in pretreated patients with advanced gastric cancer - a phase II study.Proc Am Soc Clin Oncol 22: 2003 (abstr 1374)
  3. Schmid KE, Kornek GV, Schüll B,Raderer M, Lenauer A, Depisch D,et al.Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie. 2003;26:255-8.
  4. Assersohn L, Brown G, Cunningham D,Ward C, Oates J, Waters JS,et al.Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.Ann Oncol. 2004;15:64-9.
  5. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM,et al.Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.Jpn J Clin Oncol. 2004;34:8-13.
  6. Shin SJ, Kim MK, Lee KH,Hyun MS, Kim SW, Song SK,et al.The efficacy of docetaxel and cisplatin combination chemotherapy for the treatment of advanced gastric cancer after failing to 5-fluorouracil based chemotherapy.Cancer Res Treat. 2004;36:367-71.
  7. Baek JH, Kim JG, Sohn SK,Kim DH, Lee KB, Song HS, et al.Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.J Korean Med Sci. 2005;20:966-70.
  8. Giuliani F, Molica S, Maiello E,Battaglia C, Gebbia V, Di Bisceglie M,et al.Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).Am J Clin Oncol. 2005;28:581-5.
  9. Hofheinz RD, Porta C, Hartung G, Santoro A, Hanauske AR, Kutz K, et al.BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: a phase II study group trial of the Central European Society of Anticancer-Drug Research (CESAR).Invest New Drugs. 2005;23:363-8.
  10. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH,et al.Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.Br J Cancer. 2005;92:1850-4.
  11. Kunisaki C, Imada T, Yamada R, Hatori S, Ono H, Otsuka Y,et al.Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma.Anticancer Res. 2005;25:2973-7.
  12. Park SH, Choi EY, Bang SM,Cho EK, Lee JH, Shin DB,et al.Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.Anticancer Drugs. 2005;16:621-5.
  13. Nguyen S, Rebischung C, Van Ongeval J,Flesch M, Bennamoun M, André T,et al.Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment.Bull Cancer. 2006;93:E1-6.
  14. Barone C, Basso M, Schinzari G, Pozzo C, Trigila N, D'Argento E,et al. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer.Gastric Cancer. 2007;10:104-11.
  15. Hartmann JT, Pintoffl JP, Al-Batran SE, Quietzsch D, Meisinger I, Horger M, et al.Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study.Onkologie. 2007;30:235-40.
  16. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y,et al.A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).Anticancer Res. 2007;27:2667-71.
  17. Lee KW, Kim JH, Yun T, Song EK, Na II, Shin H, et al.Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer.J Korean Med Sci. 2007;22 Suppl:S115-21.
  18. Oh SC, Park SS, Mock YJ.Phase II trial of oxaliplatin, 5-FU, and leucovorin chemotherapy for patients previously treated for advanced gastric cancer. Gastrointestinal Cancers Symposium 2007.Abstract No:53
  19. Rosati G, Bilancia D, Germano D, Dinota A, Romano R, Reggiardo G,et al.Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.Ann Oncol. 2007;18 Suppl 6:vi128-32.
  20. Abbrederis K, Lorenzen S, von Weikersthal LF,Vehling-Kaiser U, Schuster T, Rothling N, et al.Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II study in elderly patients or patients with impaired performance status.Crit Rev Oncol Hematol. 2008;66:84-90. "
  21. Jeong J, Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB,et al.Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer.Ann Oncol. 2008;19:1135-40
  22. Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, et al.A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.Cancer Chemother Pharmacol. 2008;61:631-7.
  23. Nakae S, Hirao M, Kishimoto T,Iijima S, Ishida H, Morimoto T,et al.Phase II study of bi-weekly CPT-11+CDDP for patients with gastric cancer refractory to S-1 (OGSG 0504 study).J Clin Oncol 26: 2008 (May 20 suppl; abstr 4571)
  24. Park SH, Kim YS, Hong J,Park J, Nam E, Cho EK, et al.Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study.Anticancer Drugs. 2008 ;19:303-7.
  25. Sym SJ, Chang HM, Kang HJ, Lee SS, Ryu MH, Lee JL,et al.A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.Cancer Chemother Pharmacol. 2008;63:1-8.
  26. Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H,et al.Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).Jpn J Clin Oncol. 2008;38:176-81.
  27. Tebbutt NC, Sourjina T, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, et al.ATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer--Final results of a multicentre phase II trial by the AGITG. J Clin Oncol 26: 2008 (May 20 suppl; abstr 15554)
  28. Zhong H, Zhang Y, Ma S, Ying JE, Yang Y, Yong D,et al.Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer.Anticancer Drugs. 2008;19:1013-8.
  29. Baize N, Abakar-Mahamat A, Mounier N,Berthier F, Caroli-Bosc FX.Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.Cancer Chemother Pharmacol. 2009;64:549-55.
  30. Im CK, Rha SY, Jeung HC,Jeong J, Lee SH, Noh SH,et al.A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status.Oncology. 2009;77:349-57.
  31. Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, et al.Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.Jpn J Clin Oncol. 2009;39:713-9.
  32. Lauro DiL, Fattoruso SI, Giacinti L, Vici P, Sergi D, Lopez M. Second-line chemotherapy with FOLFIRI in patients with metastatic gastric cancer (MGC) not previously treated with fluoropyrimidines.J Clin Oncol 2009; 27:15s (suppl; abstr 4549)
  33. Leary A, Assersohn L, Cunningham D,Norman AR, Chong G, Brown G,et al.A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.Cancer Chemother Pharmacol. 2009 ;64:455-62
  34. Lorizzo K, Fazio N, Radice D,Boselli S, Ariu L, Zampino MG,et al.Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.Cancer Chemother Pharmacol. 2009;64:301-6.
  35. Matsuda G, Kunisaki C, Makino H, Fukahori M, Kimura J, Sato T, et al.Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer.Anticancer Res. 2009;29:2863-7.
  36. Sun Q, Hang M, Xu W, Mao W, Hang X, Li M, et al.Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer.Jpn J Clin Oncol. 2009;39:791-6.
  37. Yoon J, Cho S, Bae W, Hwang J, Shim H, Chung I.Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer.J Clin Oncol 2009; 279 (suppl; abstr e15599)
  38. Kim SH, Lee GW, Go SI,Cho SH, Kim HJ, Kim HG,et al. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.Am J Clin Oncol. 2010;33:572-6.
  39. Kim YS, Hong J, Sym SJ,Park SH, Park J, Cho EK, et al.Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer.Cancer Res Treat. 2010 ;42:24-9.
  40. Li J, Liu X, Wang BY, Guo WJ, Yin JL,Zhu XD,et al.Phase II study of cetuximab in combination with modified FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy (EFFI study).J Clin Oncol 2010; 28:15s (suppl; abstr 4107)
  41. Recchia F, Candeloro G, Guerriero G, Piazze J, Desideri G, Necozione S,et al.Liposomal pegylated doxorubicin and oxaliplatin as salvage chemotherapy in patients with metastatic gastric cancer treated earlier.Anticancer Drugs. 2010;21:559-64.
  42. Takiuchi H, Fukuda H, Boku N,Shimada Y, Nasu J,Hamamoto Y,et al.Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407).J Clin Oncol 2010; 28:15s(suppl; abstr 4052)
  43. Yildiz R, Kalender ME, Dane F,Sevinc A, Gumus M, Camci C,et al.Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.J Oncol Pharm Pract. 2010;16:173-8.
  44. Bang YJ, Kang YK, Kang WK,Boku N, Chung HC, Chen JS, et al.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.Invest New Drugs. 2011;29:1449-58.
  45. Chan JA, Blaszkowsky LS, Enzinger PC,Ryan DP, Abrams TA, Zhu AX,et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.Ann Oncol. 2011;22:1367-73.
  46. Chon HJ, Rha SY, Park HS,Shin SJ, Kim HS, Roh JK,et al.Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.Cancer Chemother Pharmacol. 2011;68:991-9.
  47. Cunningham D, Park S, Kang Y,Chao Y, Chen L, Rees C, et al.Randomized phase II study of PEP02, irinotecan, or docetaxel as a second-line therapy in gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2011; 29 (suppl 4; abstr 6)
  48. Doi T, Muro K, Boku N, Yamada Y,Nishina T, Takiuchi H, et al.Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.J Clin Oncol. 2010;28:1904-10.
  49. Hamaguchi T, Shirao K, Ohtsu A,Hyodo I, Arai Y, Takiuchi H, et al.A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).Gastric Cancer. 2011;14:226-33.
  50. Jeon EK, Hong SH, Kim TH,Jung SE, Park JC, Won HS, et al.Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer.Cancer Res Treat. 2011;43:148-53.
  51. Kato K, Chin K, Yoshikawa T, Yamaguchi K, Tsuji Y, Esaki T, et al.Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs. 2012;30:1621-7.
  52. Kim YH, Sasaki Y, Lee KH, Rha SY, Park SH, Boku N, et al.Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results.J Clin Oncol 2011; 29 (suppl 4; abstr 87)
  53. Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, et al.An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer. 2011;47:1511-20.
  54. Zhang X, Yongqian S, Zhang F,Liang J, Ma X, Chen L, et al.Combination of paclitaxel, cisplatin, and fluorouracil in patients with advanced and metastatic gastric cancer as first- or second-line therapy: A multicenter prospective study. J Clin Oncol 2011; 29 (suppl; abstr e14561)
  55. Gallego R, Martin-Richard M, Pericay C,Garcia-Foncillas J, Queralt B, Casado E,et al.Phase II study of oxaliplatin and sorafenib in advanced gastric cancer after failure of cisplatin-fluoropyrimidine-based (PF) treatment.J Clin Oncol 2012; 30 (suppl; abstr 4079)
  56. Takiuchi H, Sasaki Y, Nishina T,Yasui H, Muro K, Tsuji A,et al.ABI-007 in the treatment of unresectable or recurrent gastric cancer refractory to fluoropyrimidine-containing regimen: Updated data from the multicenter phase II study.J Clin Oncol 2012; 30 (suppl 4; abstr 90)
  57. Schønnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM, Pfeiffer P.Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.Eur J Cancer. 2012;48:510-7.
  58. Ueda S, Hironaka S, Yasui H,Nishina T, Tsuda M, Tsumura T,et al.Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial.J Clin Oncol 2012; 30 (suppl; abstr 4002)
  59. Van Cutsem E, Yeh KH, Bang YJ,Shen L,Ajani JA, Bai YX,et al.Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1.J Clin Oncol 2012; 30 (suppl 4; abstr LBA3)
  60. Yi JH, Lee J, Lee J,Park SH, Park JO, Yim DS, et al.Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.Br J Cancer. 2012;106:1469-74.
  61. Bang YJ.A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study.J Clin Oncol 2012; 30 (suppl 34; abstr 11)
  62. Fuchs CS, Tomasek J, Cho JY, Dumitru F, Passalacqua R, Goswami C, et al. REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.J Clin Oncol 2012; 30 (suppl 34; abstr LBA5)
  63. Shimada K, Higuchi K, Hosaka N, Sasaki E, Nakayama N, Amagai K, et al.Randomized phase III trial of irinotecan plus cisplatin versus irinotecan alone after S-1 based chemotherapy failure for patients with advanced and recurrent gastric cancer (AGC) (TCOG GI-0801).J Clin Oncol 2012; 30 (suppl 34; abstr 61)
  64. Takahari D, Shitara K, Yuki S, Nakamura M, Kondo C, Tsuda T, et al. Randomized phase II study comparing dose-escalated weekly paclitaxel (wPTX) versus standard-dose wPTX for patients with previously treated advanced gastric cancer (AGC).J Clin Oncol 2012; 30 (suppl 34; abstr 64)